Montreal, Canada
Giiant Pharma Inc., founded in 2014 and headquartered in Canada, is a preclinical-stage biotech firm revolutionizing gastroenterology treatments with its unique "Towards GI Precision Delivery" approach. The company's proprietary Precision Delivery technology platform stands out by creating gut-restricted, tissue-specific small molecule drug therapeutics. Through this platform, Giiant offers a focused solution targeting varied biological markers in the realm of gastroenterology.
Their flagship program, GT-2108, exemplifies innovation in the form of microbiota-activated PDE4 inhibitor prodrugs. With enhancements in drug tolerability and therapeutic outcomes, Giiant addresses a critical need for improved treatments. Operating within the Biopharma, Biotechnology, Health Care, and Life Sciences sectors, the company secured a recent funding milestone with a $500.00K grant investment from the Crohn's & Colitis Foundation on 28 December 2023, reinforcing confidence in its innovative direction.
